Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.
Nirosen VijiaratnamChristine GirgesDilan AthaudaAlexa KingGrace AuldRachel McComishKashfia ChowdhurySimon SkeneKate MaclaganKallol Ray ChaudhuriVincenzo LibriJohn DicksonThomas FoltyniePublished in: Movement disorders clinical practice (2024)
These data suggest that DAT SBR could be a useful biomarker in disease-modifying trials, but a focus on anterior striatal subregions and incorporating disease duration into analyses may improve its utility.